CL2012000539A1 -
Compounds derived from 3- (morpholin-4-yl) -propionic acid, s1p modulators; pharmaceutical composition; Useful in the treatment, relief or prevention of diseases of the central nervous system, such as neurodegenerative disorders, Alzheimer's diseases, major depression, autism, among others.
- Google Patents
Compounds derived from 3- (morpholin-4-yl) -propionic acid, s1p modulators; pharmaceutical composition; Useful in the treatment, relief or prevention of diseases of the central nervous system, such as neurodegenerative disorders, Alzheimer's diseases, major depression, autism, among others.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Bahamas LtdfiledCriticalAbbvie Bahamas Ltd
Publication of CL2012000539A1publicationCriticalpatent/CL2012000539A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Compuestos derivados de tiomorforlina sustituida; composición farmacéutica que los comprende; y uso del compuesto para el tratamiento, alivio o prevención de enfermedades del SNC tales como trastorno neurodegenerativo, enfermedad de Alzheimer, déficit cognitivo en pacientes con esquizofrenia, depresión mayor, autismo, entre otras.Substituted thiomorphorlin derived compounds; pharmaceutical composition comprising them; and use of the compound for the treatment, alleviation or prevention of CNS diseases such as neurodegenerative disorder, Alzheimer's disease, cognitive deficit in patients with schizophrenia, major depression, autism, among others.
CL2012000539A2009-08-312012-02-29
Compounds derived from 3- (morpholin-4-yl) -propionic acid, s1p modulators; pharmaceutical composition; Useful in the treatment, relief or prevention of diseases of the central nervous system, such as neurodegenerative disorders, Alzheimer's diseases, major depression, autism, among others.
CL2012000539A1
(en)
Compounds derived from 3- (morpholin-4-yl) -propionic acid, s1p modulators; pharmaceutical composition; Useful in the treatment, relief or prevention of diseases of the central nervous system, such as neurodegenerative disorders, Alzheimer's diseases, major depression, autism, among others.
Compounds derived from heteroaryl benzenesulfonamide, modulators of nachr alfa 7; pharmaceutical composition; and its use in Alzheimer's disease, mild cognitive disorder, senile dementia, vascular dementia, among others.
Quinoline-2-carboxamide derived compounds, positive allosteric modulators of the muscarine m1 receptor; pharmaceutical composition comprising the compound; and its use in the preparation of drugs for the treatment of diseases such as Alzheimer's, pain or sleep disorders.
Agonist and antagonist compounds of the s1p5 receptor; and use of the compounds in the preparation of medicaments useful for the treatment of diseases mediated by the s1p refceptor, such as neurodedenerative diseases.
Compounds derived from substituted 6-amino-nicotinamides, as modulators of kcnq2 / 3; pharmaceutical composition that includes them, useful for the treatment and / or prophylaxis of disorders and / or selected diseases of pain, epilepsy, anxiety, cognitive diseases, among others.
Isoquinolinone derived compounds; pharmaceutical composition comprising them; and use of the compound to treat diseases such as psychosis, schizophrenia, Alzheimer's among others.
Compounds derived from substituted pyrrolidine amides, histamine h3 receptor modulators; pharmaceutical composition containing them; and its use for the treatment of diseases such as dementia, Alzheimer's, cognitive dysfunction, memory disorder, learning disorder, attention deficit, among others.